Early detection of amyloid load using F-18-florbetaben PET
Santiago Bullich, Nuria Roe-Vellve, Marta Marquie, Susan M Landau, Henryk Barthel, Victor L Villemagne, Angela Sanabria, Juan Pablo Tartari, Oscar Sotolongo-Grau, Vincent Dore, Norman Koglin, Andre Mueller, Audrey Perrotin, Aleksandar Jovalekic, Susan De Santi, Lluis Tarraga, Andrew W Stephens, Christopher C Rowe, Osama Sabri, John P Seibyl Show all
Alzheimer's Research & Therapy | BMC | Published : 2021
BACKGROUND: A low amount and extent of Aβ deposition at early stages of Alzheimer's disease (AD) may limit the use of previously developed pathology-proven composite SUVR cutoffs. This study aims to characterize the population with earliest abnormal Aβ accumulation using 18F-florbetaben PET. Quantitative thresholds for the early (SUVRearly) and established (SUVRestab) Aβ deposition were developed, and the topography of early Aβ deposition was assessed. Subsequently, Aβ accumulation over time, progression from mild cognitive impairment (MCI) to AD dementia, and tau deposition were assessed in subjects with early and established Aβ deposition. METHODS: The study population consisted of 686 sub..View full abstract
Awarded by Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health)
Awarded by DOD ADNI (Department of Defense)
Awarded by EU-EFPIA Innovative Medicines Initiatives 2 Joint Undertaking
Part of the data were acquired in clinical studies funded by Bayer Pharma AG or Piramal Imaging.Part of the data collection and sharing for this project was funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd. and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org).The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California.The FACEHBI study was supported by funds from Fundacio ACE Institut Catala de Neurociencies Aplicades, Grifols, Life Molecular Imaging, Araclon Biotech, Alkahest, Laboratorio de analisis Echevarne, and IrsiCaixa. This work has received support from the EU-EFPIA Innovative Medicines Initiatives 2 Joint Undertaking (grant no. 115952). This communication reflects the views of the authors and neither IMI nor the European Union and EFPIA are liable for any use that may be made of the information contained herein.